Results 51 to 60 of about 10,641 (185)

Effects of varenicline on neural correlates of alcohol salience in heavy drinkers [PDF]

, 2015
Background: Preclinical and emerging clinical evidence indicates that varenicline, a nicotinic partial agonist approved for\ud smoking cessation, attenuates alcohol seeking and consumption.
Momenan, Reza, Cooke, Megan, Heilig, Markus, Coe, Marion, Heilig, Markus\ua0, Gowin, Joshua, Coe, Marion A., Hommer, Daniel, Vatsalya, Vatsalya, Schwandt, Melanie L., Cooke, Megan E., Hommer, Daniel W., Gowin, Joshua L., Bartlett, Selena, Ramchandani, Vijay, Schwandt, Melanie, Ramchandani, Vijay A.\ua0   +16 more
core   +1 more source

Varenicline: A new pharmacotherapy for smoking cessation in primary care practice

South African Family Practice, 2011
Background: Cigarette smoking causes significant morbidity and mortality and is a major public health concern worldwide. Primary care doctors are in a unique position that enables them to promote smoking cessation, as smokers are more aware of their ...
N. Robson
doaj   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Efficacy of Varenicline in Patients With Severe Alcohol Dependence: A Pilot Double-Blind Randomized and Controlled Study. [PDF]

, 2019
Purpose/Background: Varenicline has proven its efficacy in the treatment of nicotine dependence, and there is also evidence that it could be helpful in the treatment of alcohol dependence.
Pfeifer, Philippe, Christoph Fehr, Fehr, Christoph, Philippe Pfeifer   +3 more
core   +2 more sources

VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY?

Рациональная фармакотерапия в кардиологии, 2015
The problem of varenicline use in patients with cardiovascular diseases is discussed. Results of large clinical trials and meta-analyses with varenicline have proven its high efficacy for treatment of nicotine addiction in adults and a small number of ...
Yu. V. Lukina, S. Yu. Martsevich
doaj   +3 more sources

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson, Thomas Parkhouse, Chloe Burke, Monika Halicka, Jennifer C. Palmer, Hend Gabr, Rebecca Wilson, Katie E. Webster, Francesca Spiga, Sarah Dawson, Deborah M. Caldwell, Jennifer Scott, Julian P. T. Higgins, Jelena Savović   +13 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens [PDF]

, 2014
BACKGROUND AND PURPOSE\ud \ud Varenicline, a neuronal nicotinic acetylcholine receptor (nAChR) modulator, decreases ethanol consumption in rodents and humans. The proposed mechanism of action for varenicline to reduce ethanol consumption has been through
Mill, D, Bartlett, S E, Simms, J A, Feduccia, A A, Yi, H Y   +4 more
core   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source